To meet global demand, IMMUNOPRECISE ANTIBODIES LTD. (TSXV: IPA) (OTC PINK: IPATF) accelerates the launch of its European B-cell facility expansion at its ModiQuest Research division in Oss, the Netherlands.
The new B-cell facility has been launched ahead of schedule, in response to client demand at ImmunoPrecise’s original B-cell facility, which opened last spring in Victoria, British Columbia.
With the current B-cell laboratory in Victoria operating at full capacity, and booked out several months, the expanded offering of the full-service B-cell facility in the EU accelerates the Company’s international growth and ability to meet international demands.
Clients will benefit from ImmunoPrecise’s global scale and combined resources. The expansion initiatives will enable the ImmunoPrecise family of companies to increase its capacity for B-cell services supporting therapeutic antibody development, provide a client-centric focus with worldwide production centers, and help to bring leading antibody discovery services to more pharmaceutical and biotech companies around the world.
“Leveraging IPAs global scale, we are able to massively accelerate the Company’s vision of bringing a single, unified Contract Research Organization (CRO) to pharmaceutical and biotech companies internationally” said Jennifer L. Bath, President and CEO. “ImmunoPrecise’s infrastructure for comprehensive antibody discovery services and global reach enables us to help ensure customer success no matter where they are located in the world.”
ImmunoPrecise’s B-cell facilities use innovative technologies that allow for B-cell screening, sorting and sequencing on a broad range of therapeutically-relevant protein families including challenging multi-membrane spanning proteins. Antibody panels identified directly from B-cells access a greater proportion of the immune repertoire compared to traditional technologies. The Company’s technology greatly increases the speed and depth of antibody discovery.
“ImmunoPrecise’s increased investment in all areas of operations offers more opportunities to clients. As we continue our global roll-out of our innovative and comprehensive antibody discovery platforms, I am reassured by the commitment to scientific excellence and client success that exists at each of our locations across the Netherlands, Canada and the United States”, said Jos Raats, President and CEO of ModiQuest Research. “We are committed to strong and sustained investment in innovation that helps international pharmaceutical and biotech companies meet their scientific and commercial goals.”
“The pharmaceutical industry has increasingly identified its need to out-source antibody discovery to a single source provider who has the expertise and cutting-edge technologies for high throughput discovery with an increased probability of identifying therapeutically relevant antibodies,” said Jennifer Bath. “We anticipate IPA’s global footprint and antibody discovery industry leadership will further the growth and expansion of our platform.”